OBJECTIVE: Despite the evidence in support of the anti-inflammatory and triglyceride-lowering effects of fenofibrate, little is known about genetic determinants of the observed heterogeneity in treatment response. This study provides the first genome-wide examination of fenofibrate effects on systemic inflammation. METHODS: Biomarkers of inflammation were measured in participants of the Genetics of Lipid Lowering Drugs and Diet Network (n=1092) before and after a 3-week daily treatment with 160 mg of fenofibrate. Two inflammatory patterns [high-sensitivity C-reactive protein-interleukin-6 and monocyte chemoattractant protein-1-tumor necrosis factor (MCP1-TNF-α)] were derived using principal component analysis. Associations between single nucleotide polymorphisms on the Affymetrix 6.0 chip and phenotypes were assessed using mixed linear models, adjusted for age, sex, study center, and ancestry as fixed effects and pedigree as a random effect. RESULTS: Before fenofibrate treatment, the strongest evidence for association was observed for polymorphisms near or within the IL2RA gene with the high-sensitivity C-reactive protein-interleukin-6 (IL6) pattern (rs7911500, P=5×10 and rs12722605, P=5×10). Associations of the MCP1-TNF-α pattern with loci in several biologically plausible genes [CYP4F8 (rs3764563), APBB1IP (rs1775246), COL13A1 (rs2683572), and COMMD10 (rs1396485)] approached genome-wide significance (P=3×10, 5×10, 6×10, and 7×10, respectively) before fenofibrate treatment. After fenofibrate treatment, the rs12722605 locus in IL2RA was also associated with the MCP1-TNF-α pattern (P=3×10). The analyses of individual biomarker response to fenofibrate did not yield genome-wide significant results, but the rs6517147 locus near the immunologically relevant IFNAR2 gene was suggestively associated with IL6 (P=7×10). CONCLUSION: We have identified several novel biologically relevant loci associated with systemic inflammation before and after fenofibrate treatment.
OBJECTIVE: Despite the evidence in support of the anti-inflammatory and triglyceride-lowering effects of fenofibrate, little is known about genetic determinants of the observed heterogeneity in treatment response. This study provides the first genome-wide examination of fenofibrate effects on systemic inflammation. METHODS: Biomarkers of inflammation were measured in participants of the Genetics of Lipid Lowering Drugs and Diet Network (n=1092) before and after a 3-week daily treatment with 160 mg of fenofibrate. Two inflammatory patterns [high-sensitivity C-reactive protein-interleukin-6 and monocyte chemoattractant protein-1-tumor necrosis factor (MCP1-TNF-α)] were derived using principal component analysis. Associations between single nucleotide polymorphisms on the Affymetrix 6.0 chip and phenotypes were assessed using mixed linear models, adjusted for age, sex, study center, and ancestry as fixed effects and pedigree as a random effect. RESULTS: Before fenofibrate treatment, the strongest evidence for association was observed for polymorphisms near or within the IL2RA gene with the high-sensitivity C-reactive protein-interleukin-6 (IL6) pattern (rs7911500, P=5×10 and rs12722605, P=5×10). Associations of the MCP1-TNF-α pattern with loci in several biologically plausible genes [CYP4F8 (rs3764563), APBB1IP (rs1775246), COL13A1 (rs2683572), and COMMD10 (rs1396485)] approached genome-wide significance (P=3×10, 5×10, 6×10, and 7×10, respectively) before fenofibrate treatment. After fenofibrate treatment, the rs12722605 locus in IL2RA was also associated with the MCP1-TNF-α pattern (P=3×10). The analyses of individual biomarker response to fenofibrate did not yield genome-wide significant results, but the rs6517147 locus near the immunologically relevant IFNAR2 gene was suggestively associated with IL6 (P=7×10). CONCLUSION: We have identified several novel biologically relevant loci associated with systemic inflammation before and after fenofibrate treatment.
Authors: Marguerite R Irvin; Edmond K Kabagambe; Hemant K Tiwari; Laurence D Parnell; Robert J Straka; Michael Tsai; Jose M Ordovas; Donna K Arnett Journal: Circ Cardiovasc Genet Date: 2010-08-21
Authors: Ezra Burstein; Jamie E Hoberg; Amanda S Wilkinson; Julie M Rumble; Rebecca A Csomos; Christine M Komarck; Gabriel N Maine; John C Wilkinson; Marty W Mayo; Colin S Duckett Journal: J Biol Chem Date: 2005-03-30 Impact factor: 5.157
Authors: Anne Tuomisto; Malin Sund; Jenni Tahkola; Anne Latvanlehto; Eeva-Riitta Savolainen; Helena Autio-Harmainen; Annikki Liakka; Raija Sormunen; Jussi Vuoristo; Anne West; Riitta Lahesmaa; Herbert C Morse; Taina Pihlajaniemi Journal: Cancer Res Date: 2008-12-15 Impact factor: 12.701
Authors: Esther M Lafuente; André A F L van Puijenbroek; Matthias Krause; Christopher V Carman; Gordon J Freeman; Alla Berezovskaya; Erica Constantine; Timothy A Springer; Frank B Gertler; Vassiliki A Boussiotis Journal: Dev Cell Date: 2004-10 Impact factor: 12.270
Authors: Dolores Corella; Donna K Arnett; Michael Y Tsai; Edmond K Kabagambe; James M Peacock; James E Hixson; Robert J Straka; Michael Province; Chao-Qiang Lai; Laurence D Parnell; Ingrid Borecki; Jose M Ordovas Journal: Clin Chem Date: 2007-04-19 Impact factor: 8.327
Authors: Edmond K Kabagambe; Stephen P Glasser; Jose M Ordovas; Daruneewan Warodomwichit; Michael Y Tsai; Paul N Hopkins; Ingrid B Borecki; Mary Wojczynski; Donna K Arnett Journal: Diabetol Metab Syndr Date: 2009-10-12 Impact factor: 3.320
Authors: Peter Durda; Jeremy Sabourin; Ethan M Lange; Mike A Nalls; Josyf C Mychaleckyj; Nancy Swords Jenny; Jin Li; Jeremy Walston; Tamara B Harris; Bruce M Psaty; William Valdar; Yongmei Liu; Mary Cushman; Alex P Reiner; Russell P Tracy; Leslie A Lange Journal: Arterioscler Thromb Vasc Biol Date: 2015-08-20 Impact factor: 8.311
Authors: Shannon L Klingel; Kaitlin Roke; Bertha Hidalgo; Stella Aslibekyan; Robert J Straka; Ping An; Michael A Province; Paul N Hopkins; Donna K Arnett; Jose M Ordovas; Chao-Qiang Lai; David M Mutch Journal: Lipids Date: 2017-10-27 Impact factor: 1.880
Authors: Dariush Mozaffarian; Edmond K Kabagambe; Catherine O Johnson; Rozenn N Lemaitre; Ani Manichaikul; Qi Sun; Millennia Foy; Lu Wang; Howard Wiener; Marguerite R Irvin; Stephen S Rich; Hongyu Wu; Majken K Jensen; Daniel I Chasman; Audrey Y Chu; Myriam Fornage; Lyn Steffen; Irena B King; Barbara McKnight; Bruce M Psaty; Luc Djoussé; Ida Y-D Chen; Jason H Y Wu; David S Siscovick; Paul M Ridker; Michael Y Tsai; Eric B Rimm; Frank B Hu; Donna K Arnett Journal: Am J Clin Nutr Date: 2014-12-10 Impact factor: 7.045
Authors: Hassan S Dashti; Stella Aslibekyan; Frank A J L Scheer; Caren E Smith; Stefania Lamon-Fava; Paul Jacques; Chao-Qiang Lai; Katherine L Tucker; Donna K Arnett; José M Ordovás Journal: Am J Hypertens Date: 2015-06-04 Impact factor: 2.689
Authors: Yiyi Ma; Caren E Smith; Chao-Qiang Lai; Marguerite R Irvin; Laurence D Parnell; Yu-Chi Lee; Lucia D Pham; Stella Aslibekyan; Steven A Claas; Michael Y Tsai; Ingrid B Borecki; Edmond K Kabagambe; José M Ordovás; Devin M Absher; Donna K Arnett Journal: Mol Nutr Food Res Date: 2015-11-23 Impact factor: 5.914
Authors: Ruth Blanco-Rojo; Javier Delgado-Lista; Yu-Chi Lee; Chao-Qiang Lai; Pablo Perez-Martinez; Oriol Rangel-Zuñiga; Caren E Smith; Bertha Hidalgo; Juan F Alcala-Diaz; Francisco Gomez-Delgado; Laurence D Parnell; Donna K Arnett; Katherine L Tucker; Jose Lopez-Miranda; Jose M Ordovas Journal: Am J Clin Nutr Date: 2016-07-20 Impact factor: 7.045
Authors: Mary K Wojczynski; Laurence D Parnell; Toni I Pollin; Chao Q Lai; Mary F Feitosa; Jeff R O'Connell; Alexis C Frazier-Wood; Quince Gibson; Stella Aslibekyan; Kathy A Ryan; Michael A Province; Hemant K Tiwari; Jose M Ordovas; Alan R Shuldiner; Donna K Arnett; Ingrid B Borecki Journal: Metabolism Date: 2015-07-03 Impact factor: 8.694